Technical Analysis for BIAF - bioAffinity Technologies, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 1.37 | -4.20% | -0.06 |
BIAF closed down 4.2 percent on Friday, November 1, 2024, on 58 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
NR7 | Range Contraction | 0.00% | |
NR7-2 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
NR7 | Range Contraction | -4.20% | |
Narrow Range Bar | Range Contraction | -4.20% | |
Wide Bands | Range Expansion | -4.20% | |
Oversold Stochastic | Weakness | -4.20% |
Alert | Time |
---|---|
Possible NR7 | about 21 hours ago |
60 Minute Opening Range Breakdown | about 21 hours ago |
Down 5% | about 21 hours ago |
10 DMA Support | 1 day ago |
Down 3% | 1 day ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biotechnology Cancer Life Sciences Biology Lung Cancer Molecular Diagnostics Diagnostic Tests Cancer Therapeutics
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biotechnology Cancer Life Sciences Biology Lung Cancer Molecular Diagnostics Diagnostic Tests Cancer Therapeutics
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.62 |
52 Week Low | 1.25 |
Average Volume | 132,745 |
200-Day Moving Average | 2.01 |
50-Day Moving Average | 1.70 |
20-Day Moving Average | 1.64 |
10-Day Moving Average | 1.39 |
Average True Range | 0.17 |
RSI (14) | 39.76 |
ADX | 27.0 |
+DI | 14.84 |
-DI | 29.51 |
Chandelier Exit (Long, 3 ATRs) | 1.73 |
Chandelier Exit (Short, 3 ATRs) | 1.77 |
Upper Bollinger Bands | 2.23 |
Lower Bollinger Band | 1.05 |
Percent B (%b) | 0.27 |
BandWidth | 72.00 |
MACD Line | -0.14 |
MACD Signal Line | -0.11 |
MACD Histogram | -0.0298 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.46 | ||||
Resistance 3 (R3) | 1.46 | 1.44 | 1.45 | ||
Resistance 2 (R2) | 1.44 | 1.41 | 1.44 | 1.44 | |
Resistance 1 (R1) | 1.40 | 1.40 | 1.39 | 1.40 | 1.43 |
Pivot Point | 1.38 | 1.38 | 1.37 | 1.38 | 1.38 |
Support 1 (S1) | 1.34 | 1.35 | 1.33 | 1.34 | 1.31 |
Support 2 (S2) | 1.32 | 1.34 | 1.32 | 1.30 | |
Support 3 (S3) | 1.28 | 1.32 | 1.30 | ||
Support 4 (S4) | 1.28 |